Kaneka (4118) Q1 2027 earnings summary

Executive summary

• Net sales for the quarter ended June 30, 2026, reached a record-high ¥223,025 million, up 12.3% year-over-year, with operating income up 83.1% to ¥14,944 million and net income up 109.8% to ¥8,941 million.

• All business units and segments reported increased sales and profits, surpassing both the prior year and previous quarter, driven by price revisions, stable supply, and overseas expansion.

• The group responded to global economic uncertainty and raw material cost increases with agile price revisions and stable supply strategies.

Financial highlights

• Net sales: ¥223,025 million (YOY +12.3%).

• Operating income: ¥14,944 million (YOY +83.1%).

• Net income: ¥8,941 million (YOY +109.8%).

• Operating income margin improved to 6.7% from 4.1% year-over-year.

• Net income per share rose to ¥148.46 from ¥67.74 year-over-year.

Outlook and guidance

• Full-year forecast (ending March 31, 2027): net sales of ¥820,000 million (+1.0%), operating income of ¥36,000 million (+9.4%), net income of ¥31,500 million (+10.8%), and net income per share of ¥523.04.

• No revision to previously announced forecasts; business environment expected to remain volatile, with ongoing cost pressures and geopolitical instability.

• Profitability improvements targeted, especially in Health Care Solutions Unit.